Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""IRINOTECAN"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 15551
Tytuł:
Incidence and non-genetic risk factors of irinotecan-induced severe neutropenia in Chinese adult inpatients.
Autorzy:
Zhang S; Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.
Yang J; Department of Pharmacy, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China.
Zhan H; Department of Pharmacy, Wuhan Jinyintan Hospital, Wuhan, China.
Yang B; Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Rong P; Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.
Luo Y; Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.
Shi C; Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.
Chen Y; Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.
Yang J; Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.
Pokaż więcej
Źródło:
Medicine [Medicine (Baltimore)] 2023 Mar 03; Vol. 102 (9), pp. e33005.
Typ publikacji:
Journal Article
MeSH Terms:
Irinotecan*/adverse effects
Lung Neoplasms*/drug therapy
Neutropenia*/chemically induced
Neutropenia*/epidemiology
Ovarian Neoplasms*/drug therapy
Adult ; Female ; Humans ; East Asian People ; Incidence ; Inpatients ; Retrospective Studies ; Risk Factors
Czasopismo naukowe
Szczegóły
Tytuł:
Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin.
Autorzy:
Kawakami T; Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan. .
Todaka A; Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Oshima K; Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Fushiki K; Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Hamauchi S; Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Tsushima T; Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Yokota T; Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Onozawa Y; Division of Clinical Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Yasui H; Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Yamazaki K; Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Jan 20; Vol. 23 (1), pp. 68. Date of Electronic Publication: 2023 Jan 20.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*
Fluorouracil*/therapeutic use
Irinotecan*/therapeutic use
Leucovorin*/therapeutic use
Pancreatic Neoplasms*/diagnosis
Pancreatic Neoplasms*/drug therapy
Biomarkers, Tumor*
Humans ; CA-19-9 Antigen ; Camptothecin ; Liposomes ; Retrospective Studies ; Treatment Outcome
SCR Disease Name:
Pancreatic Carcinoma
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Combined and targeted drugs delivery system for colorectal cancer treatment: Conatumumab decorated, reactive oxygen species sensitive irinotecan prodrug and quercetin co-loaded nanostructured lipid carriers.
Autorzy:
Liu Y; The Second Department of General Surgery, the Fourth Hospital of Hebei Medical University, Hebei Cancer Hospital, Shijiazhuang, Hebei Province, China.
Zhang H; Ward 1 of Department of Oncology, Shijiazhuang People's Hospital, Shijiazhuang, Hebei Province, China.
Cui H; Ward 2 of Department of Oncology, Shijiazhuang People's Hospital, Shijiazhuang, Hebei Province, China.
Zhang F; Ward 1 of Department of Oncology, Shijiazhuang People's Hospital, Shijiazhuang, Hebei Province, China.
Zhao L; Department of Endocrinology, the First Hospital of Xingtai, Xingtai, Hebei Province, China.
Liu Y; Department of Medical Oncology, the Fourth Hospital of Hebei Medical University, Hebei Cancer Hospital, Shijiazhuang, Hebei Province, China.
Meng Q; Department of Osteology, the First Hospital of Xingtai, Xingtai, Hebei Province, China.
Pokaż więcej
Źródło:
Drug delivery [Drug Deliv] 2022 Dec; Vol. 29 (1), pp. 342-350.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Monoclonal/*pharmacology
Antineoplastic Agents/*pharmacology
Irinotecan/*pharmacology
Nanoparticle Drug Delivery System/*chemistry
Quercetin/*pharmacology
Animals ; Antibodies, Monoclonal/administration & dosage ; Antineoplastic Agents/administration & dosage ; Cell Survival/drug effects ; Chemistry, Pharmaceutical ; Drug Carriers/chemistry ; Drug Combinations ; Drug Liberation ; Drug Stability ; Drug Synergism ; HT29 Cells ; Humans ; Irinotecan/administration & dosage ; Lipids/chemistry ; Mice ; Nanostructures ; Particle Size ; Prodrugs ; Quercetin/administration & dosage ; Reactive Oxygen Species ; Surface Properties ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Risk Factors for Septic Shock After Irinotecan-Containing Chemotherapy: An Exploratory Case-Control Study.
Autorzy:
Umemiya M; Department of Obstetrics and Gynecology, Shizuoka General Hospital, 4-27-1, Kita-Ando, Shizuoka City, Shizuoka, 420-8527, Japan.
Inayama Y; Department of Obstetrics and Gynecology, Shizuoka General Hospital, 4-27-1, Kita-Ando, Shizuoka City, Shizuoka, 420-8527, Japan. .; Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan. .
Nakatani E; Graduate School of Public Health (Medical Statistics), Shizuoka Graduate University of Public Health, Shizuoka, Japan.
Ito K; Department of Clinical Laboratory Medicine, Shizuoka General Hospital, Shizuoka, Japan.
Tsuji M; Department of Obstetrics and Gynecology, Shizuoka General Hospital, 4-27-1, Kita-Ando, Shizuoka City, Shizuoka, 420-8527, Japan.
Yoshida T; Department of Obstetrics and Gynecology, Shizuoka General Hospital, 4-27-1, Kita-Ando, Shizuoka City, Shizuoka, 420-8527, Japan.
Yu S; Department of Obstetrics and Gynecology, Shizuoka General Hospital, 4-27-1, Kita-Ando, Shizuoka City, Shizuoka, 420-8527, Japan.
Gou R; Department of Obstetrics and Gynecology, Shizuoka General Hospital, 4-27-1, Kita-Ando, Shizuoka City, Shizuoka, 420-8527, Japan.
Horikawa N; Department of Obstetrics and Gynecology, Shizuoka General Hospital, 4-27-1, Kita-Ando, Shizuoka City, Shizuoka, 420-8527, Japan.
Tani H; Department of Obstetrics and Gynecology, Shizuoka General Hospital, 4-27-1, Kita-Ando, Shizuoka City, Shizuoka, 420-8527, Japan.
Kosaka K; Department of Obstetrics and Gynecology, Shizuoka General Hospital, 4-27-1, Kita-Ando, Shizuoka City, Shizuoka, 420-8527, Japan.
Pokaż więcej
Źródło:
Drugs in R&D [Drugs R D] 2022 Dec; Vol. 22 (4), pp. 263-269. Date of Electronic Publication: 2022 Aug 20.
Typ publikacji:
Journal Article
MeSH Terms:
Enterocolitis, Neutropenic*/chemically induced
Enterocolitis, Neutropenic*/drug therapy
Irinotecan*/adverse effects
Shock, Septic*/chemically induced
Shock, Septic*/drug therapy
Female ; Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Case-Control Studies ; Genotype ; Glucuronosyltransferase/genetics ; Retrospective Studies ; Risk Factors ; Genital Neoplasms, Female/drug therapy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
MACC1 and Gasdermin-E (GSDME) regulate the resistance of colorectal cancer cells to irinotecan.
Autorzy:
Cheng MZ; State Key Laboratory of Organ Failure Research, Department of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Department of Pathology, Nanfang Hospital, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China; Department of Gastrointestinal and Hernia Surgery, Ganzhou Hospital-Nanfang Hospital, Southern Medical University, Ganzhou, Jiangxi, 341000, China.
Yang BB; State Key Laboratory of Organ Failure Research, Department of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Department of Pathology, Nanfang Hospital, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China; Department of Gastrointestinal and Hernia Surgery, Ganzhou Hospital-Nanfang Hospital, Southern Medical University, Ganzhou, Jiangxi, 341000, China.
Zhan ZT; State Key Laboratory of Organ Failure Research, Department of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Department of Pathology, Nanfang Hospital, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China; Department of Gastrointestinal and Hernia Surgery, Ganzhou Hospital-Nanfang Hospital, Southern Medical University, Ganzhou, Jiangxi, 341000, China.
Lin SM; Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, China.
Fang ZP; Department of Hepatobiliary Surgery, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, 317000, China.
Gao Y; General Surgery Center, Department of Hepatobiliary Surgery II, Guangdong Provincial, Research Center for Artificial Organ and Tissue Engineering, Guangzhou Clinical Research and Transformation Center for Artificial Liver, Institute of Regenerative Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China.
Zhou WJ; State Key Laboratory of Organ Failure Research, Department of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Department of Pathology, Nanfang Hospital, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China; General Surgery Center, Department of Hepatobiliary Surgery II, Guangdong Provincial, Research Center for Artificial Organ and Tissue Engineering, Guangzhou Clinical Research and Transformation Center for Artificial Liver, Institute of Regenerative Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China; Department of Gastrointestinal and Hernia Surgery, Ganzhou Hospital-Nanfang Hospital, Southern Medical University, Ganzhou, Jiangxi, 341000, China. Electronic address: .
Pokaż więcej
Źródło:
Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2023 Sep 03; Vol. 671, pp. 236-245. Date of Electronic Publication: 2023 Jun 02.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Gasdermins*
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/genetics
Colorectal Neoplasms*/metabolism
Humans ; Irinotecan/pharmacology ; Pyroptosis ; Trans-Activators/genetics ; Trans-Activators/metabolism
Czasopismo naukowe
Szczegóły
Tytuł:
Phase II trial of daily S-1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101.
Autorzy:
Kawashima Y; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Ishimoto O; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.; Okino Medical Clinic, Sendai, Japan.
Miyauchi E; Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Sakakibara T; Department of Respiratory Medicine, Tohoku Rosai Hospital, Sendai, Japan.
Harada T; Department of Respiratory Medicine, JCHO Hokkaido Hospital, Sapporo, Japan.
Usui K; Division of Respirology, NTT Medical Center Tokyo, Tokyo, Japan.
Inoue A; Department of Palliative Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Sugawara S; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2023 Sep; Vol. 14 (27), pp. 2804-2810. Date of Electronic Publication: 2023 Aug 17.
Typ publikacji:
Clinical Trial, Phase II; Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Squamous Cell*/drug therapy
Carcinoma, Squamous Cell*/etiology
Lung Neoplasms*/etiology
Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Epithelial Cells ; Irinotecan ; Japan ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/etiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Phase I dose-escalation study on irinotecan, cisplatin, and S-1 combination in chemotherapy-naïve patients with HER2-negative advanced gastric cancer (HERBIS-4B, OGSG 1106).
Autorzy:
Yukami H; Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Osaka, Japan.
Kawakami H; Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2, Ohno-higashi, Osakasayama, Osaka, 589-8511, Japan. kawakami_.
Yamaguchi T; Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Osaka, Japan.
Sakai D; Center for Cancer Genomics and Precision Medicine, Osaka University Hospital, Suita, Osaka, Japan.; Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Osaka, Japan.
Shimokawa T; Center for Cancer Genomics and Precision Medicine, Osaka University Hospital, Suita, Osaka, Japan.; Department of Medical Data Science, Graduate School of Medicine, Wakayama Medical University, Wakayama, Wakayama, Japan.
Kurokawa Y; Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Goto M; Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Osaka, Japan.
Satoh T; Center for Cancer Genomics and Precision Medicine, Osaka University Hospital, Suita, Osaka, Japan.
Pokaż więcej
Źródło:
International journal of clinical oncology [Int J Clin Oncol] 2023 Sep; Vol. 28 (9), pp. 1176-1182. Date of Electronic Publication: 2023 Jul 07.
Typ publikacji:
Clinical Trial, Phase I; Journal Article
MeSH Terms:
Stomach Neoplasms*/drug therapy
Febrile Neutropenia*/chemically induced
Humans ; Irinotecan/therapeutic use ; Cisplatin ; Camptothecin ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Maximum Tolerated Dose
Czasopismo naukowe
Szczegóły
Tytuł:
Design, synthesis, and biological evaluation studies of novel carboxylesterase 2 inhibitors for the treatment of irinotecan-induced delayed diarrhea.
Autorzy:
Yang Z; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
Cao Z; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China; Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510006, PR China; Key Laboratory of New Drug Discovery and Evaluation of the Guangdong Provincial Education Department, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
Wang W; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
Chen Y; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
Huang W; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China; Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510006, PR China; Key Laboratory of New Drug Discovery and Evaluation of the Guangdong Provincial Education Department, Guangdong Pharmaceutical University, Guangzhou 510006, PR China; Guangzhou Key Laboratory of Construction and Application of New Drug Screening Model Systems, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
Jiao S; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China; Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510006, PR China; Key Laboratory of New Drug Discovery and Evaluation of the Guangdong Provincial Education Department, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
Chen S; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
Chen L; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
Liu Y; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
Mao J; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
Zhang L; Key Laboratory of New Drug Discovery and Evaluation of the Guangdong Provincial Education Department, Guangdong Pharmaceutical University, Guangzhou 510006, PR China; Guangzhou Key Laboratory of Construction and Application of New Drug Screening Model Systems, Guangdong Pharmaceutical University, Guangzhou 510006, PR China. Electronic address: .
Li Z; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China; Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510006, PR China; Key Laboratory of New Drug Discovery and Evaluation of the Guangdong Provincial Education Department, Guangdong Pharmaceutical University, Guangzhou 510006, PR China; Guangzhou Key Laboratory of Construction and Application of New Drug Screening Model Systems, Guangdong Pharmaceutical University, Guangzhou 510006, PR China; Guangdong Key Laboratory of Pharmaceutical Bioactive Substances, Guangdong Pharmaceutical University, Guangzhou 510006, PR China. Electronic address: .
Pokaż więcej
Źródło:
Bioorganic chemistry [Bioorg Chem] 2023 Sep; Vol. 138, pp. 106625. Date of Electronic Publication: 2023 Jun 02.
Typ publikacji:
Journal Article
MeSH Terms:
Diarrhea*/chemically induced
Diarrhea*/drug therapy
Enzyme Inhibitors*/pharmacology
Enzyme Inhibitors*/therapeutic use
Humans ; Irinotecan/adverse effects ; Molecular Docking Simulation ; Molecular Dynamics Simulation
Czasopismo naukowe
Szczegóły
Tytuł:
Nineteen-year, real-world experience of first-line combination chemotherapy in patients with metastatic colorectal cancer: a propensity score analysis from southern Thailand.
Autorzy:
Wonglhow J; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Sathitruangsak C; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Dechaphunkul A; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Sunpaweravong P; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Pokaż więcej
Źródło:
The Journal of international medical research [J Int Med Res] 2023 Aug; Vol. 51 (8), pp. 3000605231193583.
Typ publikacji:
Journal Article
MeSH Terms:
Colonic Neoplasms*
Rectal Neoplasms*
Humans ; Irinotecan/therapeutic use ; Oxaliplatin/therapeutic use ; Propensity Score ; Retrospective Studies ; Thailand ; Drug Therapy, Combination
Czasopismo naukowe
Szczegóły
Tytuł:
Natural deletion of mouse carboxylesterases Ces1c/d/e impacts drug metabolism and metabolic syndrome development.
Autorzy:
Gan C; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
Wang J; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
Wang Y; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
Martínez-Chávez A; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
Hillebrand M; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
de Vries N; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
Beukers J; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
Lebre MC; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
Wagenaar E; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
Rosing H; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
Klarenbeek S; Experimental Animal Pathology Facility, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
Bleijerveld OB; Proteomics Core Facility, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
Song JY; Experimental Animal Pathology Facility, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
Altelaar M; Proteomics Core Facility, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, and Netherlands Proteomics Center, Padualaan 8, Utrecht 3584 CH, The Netherlands.
Beijnen JH; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CS, the Netherlands.
Schinkel AH; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands. Electronic address: .
Pokaż więcej
Źródło:
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2023 Aug; Vol. 164, pp. 114956. Date of Electronic Publication: 2023 May 31.
Typ publikacji:
Journal Article
MeSH Terms:
Carboxylic Ester Hydrolases*/genetics
Carboxylic Ester Hydrolases*/metabolism
Metabolic Syndrome*
Prodrugs*
Animals ; Female ; Male ; Mice ; Inflammation ; Irinotecan ; Lipids ; Mammals ; Obesity/metabolism
Czasopismo naukowe
Szczegóły
Tytuł:
Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study.
Autorzy:
Dai X; Department of Oncology, First people's Hospital of Yancheng, Yancheng, China.; Yancheng Clinical College of Xuzhou Medical University, Xuzhou, China.; The Fourth Affiliated Hospital of Nantong University, Nantong, China.
Tao L; Department of Oncology, First people's Hospital of Yancheng, Yancheng, China.; Yancheng Clinical College of Xuzhou Medical University, Xuzhou, China.; The Fourth Affiliated Hospital of Nantong University, Nantong, China.
Wang J; Yancheng Dafeng People's Hospital, Yancheng, China.
Wu W; Department of Oncology, Northern Jiangsu People's Hospital, Clinical Medical College of Yangzhou University, Yangzhou, China.
Bian W; Department of Oncology, First people's Hospital of Yancheng, Yancheng, China.; Yancheng Clinical College of Xuzhou Medical University, Xuzhou, China.; The Fourth Affiliated Hospital of Nantong University, Nantong, China.
Dai X; Department of Oncology, Hongze People's Hospital of Huai'an City, China.
Chen S; Department of Oncology, First people's Hospital of Yancheng, Yancheng, China.; Yancheng Clinical College of Xuzhou Medical University, Xuzhou, China.; The Fourth Affiliated Hospital of Nantong University, Nantong, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Aug; Vol. 12 (15), pp. 16108-16118. Date of Electronic Publication: 2023 Jun 16.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Squamous Cell*/drug therapy
Esophageal Neoplasms*/pathology
Esophageal Squamous Cell Carcinoma*/drug therapy
Esophageal Squamous Cell Carcinoma*/etiology
Humans ; Irinotecan ; Prospective Studies ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
3-deazaneplanocin A, a histone methyltransferase inhibitor, improved the chemoresistance induced under hypoxia in melanoma cells.
Autorzy:
Hosokawa M; Laboratory of Pharmaceutics, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe, 658-8558, Japan. Electronic address: .
Tetsumoto S; Laboratory of Pharmaceutics, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe, 658-8558, Japan.
Yasui M; Laboratory of Pharmaceutics, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe, 658-8558, Japan.
Kono Y; Laboratory of Pharmaceutics, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe, 658-8558, Japan.
Ogawara KI; Laboratory of Pharmaceutics, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe, 658-8558, Japan.
Pokaż więcej
Źródło:
Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2023 Oct 15; Vol. 677, pp. 26-30. Date of Electronic Publication: 2023 Aug 02.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Histones*/metabolism
Melanoma*/genetics
Humans ; Animals ; Mice ; Histone Methyltransferases/genetics ; Irinotecan ; Drug Resistance, Neoplasm ; Cell Line, Tumor ; Enhancer of Zeste Homolog 2 Protein/metabolism ; Enzyme Inhibitors/pharmacology ; DNA Methylation ; RNA, Small Interfering/metabolism ; Tumor Microenvironment
Czasopismo naukowe
Szczegóły
Tytuł:
Label-free drug response evaluation of human derived tumor spheroids using three-dimensional dynamic optical coherence tomography.
Autorzy:
Abd El-Sadek I; Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, 305-8573, Japan.; Department of Physics, Faculty of Science, Damietta University, New Damietta City, Damietta, 34517, Egypt.
Shen LT; Clinical Research and Regional Innovation, Faculty of Medicine, University of Tsukuba, Ibaraki, 305-8575, Japan.
Mori T; Clinical Research and Regional Innovation, Faculty of Medicine, University of Tsukuba, Ibaraki, 305-8575, Japan.
Makita S; Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, 305-8573, Japan.
Mukherjee P; Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, 305-8573, Japan.
Lichtenegger A; Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, 305-8573, Japan.; Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Währinger Gürtel 18-20, 4L, 1090, Vienna, Austria.
Matsusaka S; Clinical Research and Regional Innovation, Faculty of Medicine, University of Tsukuba, Ibaraki, 305-8575, Japan.
Yasuno Y; Computational Optics Group, University of Tsukuba, Tsukuba, Ibaraki, 305-8573, Japan. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Sep 16; Vol. 13 (1), pp. 15377. Date of Electronic Publication: 2023 Sep 16.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Colonic Neoplasms*
Breast Neoplasms*
Humans ; Female ; Tomography, Optical Coherence ; Algorithms ; Drug Evaluation ; Irinotecan/pharmacology ; Paclitaxel
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
Autorzy:
Boige V; Department of Cancer Medicine, Gustave Roussy, Villejuif, France.; INSERM UMR-S1138, Centre de Recherche des Cordeliers-Sorbonne Université- Université de Paris Cité, Paris, France.
Blons H; INSERM UMR-S1138, Centre de Recherche des Cordeliers-Sorbonne Université- Université de Paris Cité, Paris, France.; Department of Biochemistry, Molecular Oncology and Pharmacogenetics, European Georges Pompidou Hospital, APHP-Centre, Université Paris Cité, Paris Cancer Institute CARPEM, Paris, France.
François E; Department of Medical Oncology, Antoine Lacassagne Centre, Nice, France.
Ben Abdelghani M; Department of Medical Oncology, Paul Strauss Centre, Strasbourg, France.
Phelip JM; Departement of Hepato-gastroenterology, Saint Etienne Hospital, Saint Priest en Jarez, France.
Le Brun-Ly V; Departement of Medical Oncology and Radiotherapy, Dupuytren Hospital, Limoges, France.
Mineur L; Departement of Clinical Research, Sainte Catherine Institute, Avignon, France.
Galais MP; Department of Gastro-enterology, François Baclesse Centre, Caen, France.
Villing AL; Departement of Medical Oncology, Auxerre Hospital, Auxerre, France.
Hautefeuille V; Departement of Hepato-gastroenterology, Amiens Hospital, Amiens, France.
Miglianico L; Department of Radiotherapy, Saint Grégoire Hospital, Saint-Grégoire, France.
De La Fouchardière C; Department of Medical Oncology, Leon Bérard Centre, University Lyon I, Lyon, France.
Genet D; Departement of Oncology and Radiotherapy, François Chénieux Clinic, Limoges, France.
Levasseur N; Department of Oncology, Jean Rougier Hospital, Cahors, France.
Levaché CB; Departement of Oncology and Radiotherapy, Francheville Polyclinic, Périgueux, France.
Penel N; Pole of Oncology, Oscar Lambret Centre, Lille, France.
Mitry E; Department of Medical Oncology, Paoli Calmettes Institute, Marseille, France.
Jacquot S; Department of Radiotherapy, Clementville Clinic, Montpellier, France.
Aparicio T; Department of Gastro-enterology, Saint Louis Hospital, APHP, Université Paris Cité, Paris, France.
Brument E; UCGI, PRODIGE Intergroup, Unicancer, Paris, France.
Gourgou S; Biometry Unit, Montpellier Cancer Institute, Montpellier, France.
Castan F; Biometry Unit, Montpellier Cancer Institute, Montpellier, France.
Bouché O; Department of Digestive Oncology, CHU Reims, Université Reims Champagne-Ardenne, Reims, France.
Pokaż więcej
Źródło:
JAMA network open [JAMA Netw Open] 2023 Sep 05; Vol. 6 (9), pp. e2333533. Date of Electronic Publication: 2023 Sep 05.
Typ publikacji:
Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; Journal Article
MeSH Terms:
Colonic Neoplasms*
Rectal Neoplasms*
Male ; Humans ; Aged ; Middle Aged ; Cetuximab/therapeutic use ; Irinotecan ; Leucovorin/therapeutic use ; Disease Progression
Czasopismo naukowe
Szczegóły
Tytuł:
Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS).
Autorzy:
Shitara K; National Cancer Center Hospital East, Kashiwa-Shi, Chiba, 277-8577, Japan. .; Nagoya University Graduate School of Medicine, Nagoya, Japan. .
George B; Medical College of Wisconsin, Milwaukee, WI, USA.
Taieb J; Hôpital Européen Georges Pompidou, Université Paris-Cité, SIRIC CARPEM, Paris, France.
Sundar R; National University Health System, Singapore, Singapore.
Fakih MG; City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Makris L; Stathmi, Inc., New Hope, PA, USA.
Benhadji KA; Taiho Oncology, Inc., Princeton, NJ, USA.
Ghidini M; Azienda Ospedaliera di Cremona, Cremona, Italy.
Pokaż więcej
Źródło:
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2023 Sep; Vol. 149 (11), pp. 9361-9374. Date of Electronic Publication: 2023 May 22.
Typ publikacji:
Clinical Trial, Phase III; Randomized Controlled Trial; Journal Article
MeSH Terms:
Colorectal Neoplasms*/pathology
Stomach Neoplasms*/drug therapy
Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Drug Combinations ; Esophagogastric Junction/pathology ; Irinotecan/therapeutic use ; Paclitaxel/therapeutic use ; Pyrrolidines ; Trifluridine/therapeutic use
Czasopismo naukowe
Szczegóły
Tytuł:
Predicting conversion surgery in patients with locally advanced pancreatic cancer after modified FOLFIRINOX treatment.
Autorzy:
Ninomiya R; Department of Hepato-Biliary-Pancreatic Surgery and Pediatric Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan. Electronic address: .
Abe S; Department of Hepato-Biliary-Pancreatic Surgery and Pediatric Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Chiyoda T; Department of Hepato-Biliary-Pancreatic Surgery and Pediatric Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Kogure R; Department of Hepato-Biliary-Pancreatic Surgery and Pediatric Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Kimura A; Department of Hepato-Biliary-Pancreatic Surgery and Pediatric Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Komagome M; Department of Hepato-Biliary-Pancreatic Surgery and Pediatric Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Maki A; Department of Hepato-Biliary-Pancreatic Surgery and Pediatric Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Beck Y; Department of Hepato-Biliary-Pancreatic Surgery and Pediatric Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Pokaż więcej
Źródło:
Asian journal of surgery [Asian J Surg] 2023 Sep; Vol. 46 (9), pp. 3542-3548. Date of Electronic Publication: 2023 Apr 20.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Pancreatic Neoplasms*/surgery
Humans ; Irinotecan/therapeutic use ; Fluorouracil/therapeutic use ; Neoadjuvant Therapy ; Retrospective Studies
Czasopismo naukowe
Szczegóły
Tytuł:
Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer.
Autorzy:
Nara K; Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan.
Taguchi A; Department of Obstetrics and Gynecology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. .; Laboratory of Human Single Cell Immunology, World Premier International Immunology Frontier Research Center (WPI-IFReC), Osaka University, Suita, Japan. .
Yamamoto T; Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan.; The Education Center for Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
Hara K; Department of Economics, The University of Arizona, Tucson, USA.
Tojima Y; Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan.
Honjoh H; Department of Obstetrics and Gynecology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Nishijima A; Department of Obstetrics and Gynecology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Eguchi S; Department of Obstetrics and Gynecology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Miyamoto Y; Department of Obstetrics and Gynecology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Sone K; Department of Obstetrics and Gynecology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Mori M; Department of Obstetrics and Gynecology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Takada T; Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan.
Osuga Y; Department of Obstetrics and Gynecology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Pokaż więcej
Źródło:
International journal of clinical oncology [Int J Clin Oncol] 2023 Sep; Vol. 28 (9), pp. 1207-1217. Date of Electronic Publication: 2023 Jun 22.
Typ publikacji:
Journal Article
MeSH Terms:
Ovarian Neoplasms*/pathology
Antineoplastic Agents*/therapeutic use
Humans ; Female ; Carcinoma, Ovarian Epithelial/drug therapy ; Bevacizumab/therapeutic use ; Doxorubicin/therapeutic use ; Gemcitabine ; Irinotecan/therapeutic use ; Polyethylene Glycols ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Szczegóły
Tytuł:
Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer.
Autorzy:
Wilbur HC; Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore, Maryland.
Durham JN; Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore, Maryland.
Lim SJ; Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore, Maryland.
Purtell K; Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore, Maryland.
Bever KM; Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore, Maryland.
Laheru DA; Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore, Maryland.
De Jesus-Acosta A; Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore, Maryland.
Azad NS; Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore, Maryland.
Wilt B; Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore, Maryland.
Diaz LA; Memorial Sloan Kettering Cancer Center, New York, New York.
Le DT; Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore, Maryland.
Wang H; Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore, Maryland.
Pokaż więcej
Źródło:
Cancer research communications [Cancer Res Commun] 2023 Aug 28; Vol. 3 (8), pp. 1672-1677. Date of Electronic Publication: 2023 Aug 28 (Print Publication: 2023).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Pancreatic Neoplasms*/drug therapy
Adenocarcinoma*/drug therapy
Humans ; Docetaxel ; Irinotecan ; Capecitabine/adverse effects ; Cisplatin/therapeutic use ; Gemcitabine
SCR Disease Name:
Pancreatic Carcinoma
Czasopismo naukowe
Szczegóły
Wyświetlanie 1-20 z 15551

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies